Caplin Point Laboratories Limited (NSE: CAPLIPOINT)

Market Cap	149.36B
Revenue (ttm)	18.33B
Net Income (ttm)	4.94B
Shares Out	n/a
EPS (ttm)	64.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Sep 23, 2024

Volume	60,778
Open	1,945.85
Previous Close	1,942.80
Day's Range	1,935.00 - 1,982.00
52-Week Range	1,178.00 - 2,176.75
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Caplin Point Laboratories

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point La...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 3,406
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CAPLIPOINT

Financial Performance

In 2023, Caplin Point Laboratories's revenue was 16.96 billion, an increase of 15.51% compared to the previous year's 14.68 billion. Earnings were 4.57 billion, an increase of 21.48%.